A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)

Project: Research

Project Details

StatusActive
Effective start/end date23/05/2323/05/25

Keywords

  • clinical trial
  • HER2 negative
  • breast cancer
  • advanced cancer
  • estrogen receptor
  • protein degrader
  • Pfizer
  • ARV-471